Overlapping roles for toxins in clostridium difficile infection

Journal of Infectious Diseases

Volumn 209, Issue 1, 2014, Pages 9-11

  Young, Vincent B ^a   Hanna, Philip C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antibiotic associated colitis; C. difficile; isogenic mutant; toxin

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; VIRULENCE FACTOR;

BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; HAMSTER MODEL; NONHUMAN; NOTE; PRIORITY JOURNAL; WILD TYPE;

ANTIBIOTIC-ASSOCIATED COLITIS; C. DIFFICILE; ISOGENIC MUTANT; TOXIN;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; FEMALE; HUMANS;

EID: 84891361992     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit461     Document Type: Note

References (19)

1. Stevens DL, Aldape MJ, Bryant AE. Lifethreatening clostridial infections. Anaerobe 2012; 18:254-9.
2. Swaminathan S. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J 2011; 278:4467-85.
3. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55(suppl 2): S65-70.
4. Pacheco SM, Johnson S. Important clinical advances in the understanding of Clostridium difficile infection. Curr Opin Gastroenterol 2013; 29:42-8.
5. Bartlett JG. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 2010; 1213: 62-9.
6. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK, Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140-5.
7. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49.
8. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012; 20:313-9.
9. Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011; 60(Pt 8):1070-9.
10. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009; 33(suppl 1): S33-6.
11. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 2012; 4:149-58.
12. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18:247-63.
13. Stiles BG,Wigelsworth DJ, Popoff MR, Barth H. Clostridial binary toxins: iota and C2 family portraits. Front Cell Infect Microbiol 2011; 1:11.
14. Geric B, Carman RJ, Rupnik M, et al. Binary toxin-producing, large clostridial toxinnegative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193:1143-50.
15. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-3.
16. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9.
17. Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infections. J Infect Dis 2013; 207:1498-504.
18. Adamu BO, Lawley TD. Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr Opin Microbiol 2013 Jul 15. pii: S1369-5274(13) 00083-0. doi: 10.1016/j.mib.2013.06.009. [Epub ahead of print].
19. Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial ecosystems therapeutics: a new paradigm in medicine? Beneficial Microbes 2013; 4:53-65.